open access

Vol 56, No 2 (2022)
Letter to the Editors
Submitted: 2021-12-13
Accepted: 2021-12-20
Published online: 2022-01-14
Get Citation

LRRK2 R1441C mutation causing Parkinson’s Disease in an Egyptian family

Shan Ali1, Zbigniew K Wszolek1
·
Pubmed: 35029295
·
Neurol Neurochir Pol 2022;56(2):191-192.
Affiliations
  1. Department of Neurology, Mayo Clinic College of Medicine, Jacksonville, Florida, United States

open access

Vol 56, No 2 (2022)
Letters to the Editors
Submitted: 2021-12-13
Accepted: 2021-12-20
Published online: 2022-01-14

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

Egyptian, leucine-rich repeat kinase 2 gene, Parkinson’s Disease, R1441C mutation

About this article
Title

LRRK2 R1441C mutation causing Parkinson’s Disease in an Egyptian family

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 56, No 2 (2022)

Article type

Letter to the Editors

Pages

191-192

Published online

2022-01-14

Page views

4948

Article views/downloads

549

DOI

10.5603/PJNNS.a2022.0008

Pubmed

35029295

Bibliographic record

Neurol Neurochir Pol 2022;56(2):191-192.

Keywords

Egyptian
leucine-rich repeat kinase 2 gene
Parkinson’s Disease
R1441C mutation

Authors

Shan Ali
Zbigniew K Wszolek

References (5)
  1. Peng F, Sun YM, Chen C, et al. The heterozygous R1441C mutation of leucine-rich repeat kinase 2 gene in a Chinese patient with Parkinson disease: a five-year follow-up and literatures review. J Neurol Sci. 2017; 373: 23–26.
  2. Srivatsal S, Cholerton B, Leverenz JB, et al. Cognitive profile of LRRK2-related Parkinson's disease. Mov Disord. 2015; 30(5): 728–733.
  3. Milanowski ŁM, Ross OA, Friedman A, et al. Genetics of Parkinson's disease in the Polish population. Neurol Neurochir Pol. 2021; 55(3): 241–252.
  4. Benamer HTS, de Silva R. LRRK2 G2019S in the North African population: a review. Eur Neurol. 2010; 63(6): 321–325.
  5. Fiandaca MS, Lonser RR, Elder JB, et al. Advancing gene therapies, methods, and technologies for Parkinson's Disease and other neurological disorders. Neurol Neurochir Pol. 2020; 54(3): 220–231.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl